Home

CATHY KLEMA

CIK 1181157 · last filed 2026-06-10

CATHY KLEMA is a corporate insider who has filed 36 SEC Form 4 insider transactions across 5 companies since 2007. The most recent filing, for OPRX, was dated Jun 10, 2026. Across all open-market trades the lifetime net is −$2.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.4M across reported positions. 20 SEC filings were submitted jointly with PHARMACEUTICAL PRODUCT DEVELOPMENT INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.44M

Companies

5

Total Filings

36

Lifetime Open-Market Net

-$2.48M

Filer Profile

Related Filers
PHARMACEUTICAL PRODUCT DEVELOPMENT INC — 20 joint filings, latest 2011-01-04
Actavis plc — 11 joint filings, latest 2019-05-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OPRX Director 56,137 $7.18 $403.1K $0 5 2026-06-10
Allergan plc (AGN) Delisted Director 25,081 — — $0 7 2019-05-02
ACT Director 21,027 $49.50 $1.04M $0 2 2015-06-08
Actavis, Inc. (WPI) Delisted Director 44,432 — — -$1.70M 7 2012-08-01
PHARMACEUTICAL PRODUCT DEVELOPMENT INC (PPDI) Delisted Director 16,199 — — -$774.3K 12 2011-01-04

Recent Filings

36 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-10 OPRX Grant (A) +34,517 $0 EDGAR
2025-06-12 OPRX Grant (A) +9,868 $0 EDGAR
2025-02-04 OPRX Exer (M) +5,109 $0 EDGAR
2024-06-11 OPRX Grant (A) +6,643 $0 EDGAR
2024-02-06 OPRX Grant (A) — $0 EDGAR
2019-05-02 Allergan plc (AGN) Delisted Tax (F) −953 -$140.1K EDGAR
2019-03-13 Allergan plc (AGN) Delisted Other (J) +410 $0 EDGAR
2018-05-04 Allergan plc (AGN) Delisted Grant (A) +1,985 $299.9K EDGAR
2017-05-05 Allergan plc (AGN) Delisted Grant (A) +1,223 $299.9K EDGAR
2016-08-09 Allergan plc (AGN) Delisted Grant (A) +201 $49.9K EDGAR
Showing 1–10 of 36
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.